Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 50 mg/ml - injection - excipient ingredients: human immunoglobulin a; octoxinol 10; tributyl phosphate; maltose; water for injections - replacement therapy: primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiencies; wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital acquired immune deficiency syndrome (aids) who have repeated bacterial infections; immunomodulatory effect: idiopathic thrombocytopenic purpura, in adults or children with a high risk of bleeding or prior to surgery to correct platelet count. guillain barre syndrome. kawasaki disease. allogeneic bone marrow transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; zoster immunoglobulin, quantity: 200 iu - injection, solution - excipient ingredients: water for injections; glycine; human immunoglobulin a - indications as at 8 august 2002 : zoster immunoglobulin is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma); b. congenital or acquired immunodeficiency; c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact; b. playmate contact (>1 hour play indoors); c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward); d. newborn contact (newborn of mother who had onset of chickenpox <5 days before delivery or within 48 hours after delivery); e. premature infant (>= 28 weeks gestation) whose mother lacks a prior history of chickenpox; f. premature infant (< 28 weeks gestation or <= 1000g) regardless of maternal history. 3. negative or unknown history of chickenpox. 4. if zoster immunoglobulin can be administered within 96 hours after exposure. zoster immunoglobulin, normal immunoglobulin (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - human herpesvirus 6 (unii: 4ix4vp35cr) (human herpesvirus 6 - unii:4ix4vp35cr) - for the temporary relief of symptoms related to hhv-6, including fatigue, cognitive and neurological complaints.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to hhv-6, including fatigue, cognitive and neurological complaints.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - human herpesvirus 6 (unii: 4ix4vp35cr) (human herpesvirus 6 - unii:4ix4vp35cr) - for the temporary relief of symptoms related to hhv-6, including fatigue, cognitive and neurological complaints.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to hhv-6, including fatigue, cognitive and neurological complaints.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - ct748 - cytomegalovirus (human herpesvirus 5) ivds - for the determination of cytomegalovirus markers in human clinical specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd molecular division - ct748 - cytomegalovirus (human herpesvirus 5) ivds - for the determination of cytomegalovirus(cmv)markers in human clinical specimens

Australia - English - Department of Health (Therapeutic Goods Administration)

beckman coulter australia pty ltd - ct748 - cytomegalovirus (human herpesvirus 5) ivds - the access cmv igg/igm assay is a paramagnetic-particle, chemiluminescent immunoassay for the semi-quantitative determination of igg/ igm antibodies to cytomegalovirus (cmv) in human serum and plasma (edta, heparin) using the access immunoassay systems.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - ct747 - epstein-barr virus (human herpesvirus 4) ivds - for the determination of epstein barr virus markers in human clinical specimens

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct749 - herpes simplex virus (hsv) (human herpesvirus 1 & 2) ivds - immunoassays for the in vitro qualitative determination of igg class antibodies to hsv-1 and hsv-2 in human serum and plasma. the test are intended for use as an aid in the assessment of immune status and as aid in the diagnosis of hsv infection

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - ct749 - herpes simplex virus (hsv) (human herpesvirus 1 & 2) ivds - for the determination of antibodies to the herpes simplex virus (hsv) in human serum and plasma